UCI 趙 Chao Family Comprehensive Cancer Center

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Managers:
Stephanie Osorio
Judit Castellanos

Clinical Research Coordinators:
Alice Ting
Kelsey Edwards
Georgina Alvarez-Diaz
Melisa Duvnjak
Makena Castillo
Cristian Franco
Jeffrey Caluag
Nathalie Barragan
Phoebe Lee
Brian Rubio
Aracely Corona

Data Coordinators:
Heather Franson
Mario Diaz
Sarahy Martinez

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Myeloproliferative Neoplasm

ET, PV, or MF

UCI 20-50
N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 15/27

CRC: Dr. Fleischman's Lab

JAK2-m

UCI 26-12 (NEW)
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Accrual: 0/5
CRC: Kelsey E.

ET, PV, or MF

26 CTP.LEUK02 (NEW)
A Random Open Label Trial Comparing Momelotinib vs Dose Adjusted Ruxolitinib Tx Naive
Accrual: 0/5
CRC: TBD

Ph- MPNs

ETCTN 10675
A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Accrual: 2/5

CRC: Georgina A.

UCI 22-118
Treating Anemia in Myeloproliferative Neoplasms with Repurposed Drugs (Nelfinavir) that Restore Iron Delivery to the Bone Marrow

Accrual 0/10

CRC: Kelsey E.

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Intensive

IDH2-m

MM1MDS-A01
Randomized Phase II Trial of Enasidenib-Based Therapies vs Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Accrual: 0/5

CRC: Georgina A.

Parent Screening Study

MYELOMATCH
MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Accrual: 0/5

CRC: Makena Belle Castillo

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low Risk

R/R to EPOs, Luspatercept, & HMAs

UCI 21-239

IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 2/5

CRC: Georgina A.

Non-Intensive

2nd Line (Cohort F)

UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 3/10

CRC: Georgina A.

Myelodysplastic Syndrome

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Acute Myeloid Leukemia

Intensive

NPM1-m or KMT2A-r

ETCTN-10596
SNDX-5613 + Daunorubicin and Cytarabine in Newly Dx AML (NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged)

Accrual: 0/5

CRC: Georgina A.

NPM1-m or KMT2A-r

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 10/10

CRC: Georgina A.

Non-Intensive

NPM1-m or KMT2A-r

UCI 25-20
Assessing Ziftomenib in Combination with Either SOC Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Newly Dx NPM1-m or KMT2A-r AML
Accrual: 6/5

CRC: Georgina A.

Cohort A, B, G (TP53), I

UCI 25-193
ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 3/10

CRC: Nathalie B.

Cohort Part D

UCI 22-81 (Paused)
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239
Accrual: 4/6
CRC: Georgina A.

ETCTN-10630 (Suspended)
Ladademstat in Combination with Venetoclax and Azacitidine in Patients with Post MDS Transformation to AML

Accrual: 2/7

CRC: Georgina A.

UCI 26-169 (NEW)
Phase IIb/Phase III Double-blinded, Randomized Study of IPN60340+Aza-Ven vs. Placebo+Aza-Ven in Participants with Newly Dx AML Who Are Ineligible for Intensive Chemotherapy
Accrual: 0/5

CRC: TBD

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Maintenance

IDH1-R132-m in CR/CRi

UCI 25-90 (NEW)
Olutasidenib in Combination with Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated AML
Accrual: 0/5

CRC: TBD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

Part A, B, C

UCI 22-81 (Completed)
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239
Accrual: 4/6
CRC: Georgina A.

KMT2A-r or NPM1-m

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML
Accrual: 10/10
CRC: Georgina A.

KMT2A-r or NPM1-m

UCI 23-154
Ziftomenib combinations for the KMT2A-rearranged/NPM1 mutant R/R AML
Accrual: 3/5
CRC: Georgina A.

Age 18-80 years

UCI 25-105 (NEW)
Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of L-Annamycin + Cytarabine vs Placebo + Cytarabine as 2L Therapy for Remission Induction in R/R AMLs
Accrual: 0/5
CRC: TBD

Cohort C

UCI 25-193
ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies
Accrual: 3/10
CRC: Nathalie B.

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

Age ≥ 60 years or <60 if non-intensive CD19+

SWOG-21CTP-LEUK01
Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Dx Ph+ B-ALL

Accrual: 1/5
CRC: Makena Belle Castillo

Age ≥ 75 years or >18 if non-intensive CD22+

A041703: Cohort 3
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-, CD22+ B-Lineage ALL in Newly Dx Older Adults or Adults with R/R Disease
Accrual: 2/5

CRC: Makena Belle Castillo

Ph- only

Age ≥ 18 years & < 40 years CD22+

A041501
Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15

CRC: Makena Belle Castillo

Age ≥ 18 years

UCI 25-104 (On Hold)
subcutaneous blinatumomab vs. intravenous blinatumomab in newly diagnosed adults with (Ph)- B cell precursor ALL

Accrual: 0/5

CRC: TBD

Age ≥ 60 years, CD22+

A041703: Cohort 1
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage ALL in Newly Dx Older Adults or Adults with R/R Disease
Accrual: 2/5

CRC: Makena Belle Castillo

Acute Lymphoblastic Leukemia

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

Ph- only

Age ≥ 12 years, CD19+

26-53 (NEW)
A PhII/III Randomized, Open-Label, Comparison Study of MK-1045 vs Blinatumomab in patients with R/R CD19+ B-ALL

Accrual:0/5
CRC: Makena

Age ≥ 18 years, CD22+

A041703: Cohort 2
Inotuzumab Ozogamicin Followed by Blinatumomab for Ph- CD22+ B-ALL in Newly Dx Older Adults or Adults with R/R Disease
Accrual: 2/5

CRC: Makena

Acute Promyelocytic Leukemia

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Age ≥18 to <71 years

UCI 25-166
Phase 3 Study Evaluating the Efficacy and Safety of QTX-2101 in Newly Diagnosed Acute Promyelocytic Leukemia

Accrual: 0/2
CRC: Makena Belle Castillo

Hemophagocytic Lymphohistiocytosis

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

≥ 5 of 8 HLH-2004 diagnostic criteria

UCI 23-189
Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 2/6

CRC: Alice Ting

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

High Risk

S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 5/10

CRC: Kelsey E.

Slot based

UCI 25-192

Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patient with Previously Untreated CLL

Accrual: 1/7

CRC: Aracely C.

Consolidation

High-Risk

UCI 24-32

Epcoritamab as Consolidation Therapy for High-risk Patients with Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor

Accrual: 0/24

CRC: Kelsey E.

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

≥ 1 Line

Open enrollment

UCI 24-190
A Phase III Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax + Rituximab in Patients With R/R CLL/SLL

Accrual: 1/7

CRC: Kelsey E. McAbee

cBTKi, ncBTKi, and BCL-2i exposed

UCI 26-36 (NEW)
Phase 2 Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) (CLL) or (SLL) Previously Exposed to a BTKi and a BCL-2i
Accrual: 0/5

CRC: Aracely C.

(del)17p, TP53

UCI 26-43 (NEW)
A Phase III Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in cBTKi Pretreated Relapsed or Refractory CLL/SLL
Accrual: 0/5

CRC: TBD

unmutated IGHV

UCI 26-65 (NEW)
Study of Surovatamig as Consolidation Therapy vs Observation after First-line Induction Therapy in Participants with CLL/SLL with Unmutated IGHV (SOUNDTRACK-C1)
Accrual: TBD
CRC: TBD

≥ 2 Lines

Cohort 1 (CLL/SLL)

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

≥ 3 Lines

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

1 – 4 Lines

Cohort 2

UCI 23-167
Phase I- TERN-701 in patients w/CML

Accrual: 2/5

CRC: Kelsey E.

+2 Lines

Cohort 2m (BCR::ABL1 resistance mutation)

UCI 23-167
Phase I- TERN-701 in patients w/CML

Accrual: 2/5

CRC: Kelsey E.

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

HSCT Eligible

SWOG-S2213

Phase III, Randomized Study of Dara-VCD Induction Followed by Autologous SCT or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Accrual: 2/5

CRC: Alice Ting

CAR-T Eligible

UCI 26-116 (NEW)

A Randomized Phase 3 Study to evaluate the efficacy and safety of NXC-201 compared with CyBor in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

Accrual: 0/3

CRC: Cristian Franco

AL Amyloidosis

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Anti-BCMA

UCI 23-158
Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma
Accrual: 2/6
CRC: Alice Ting

BsAbs

UCI 26-69 (NEW)
Sequential integration of bispecific monoclonal antibodies into Treatment of Newly Diagnosed Multiple Myeloma

Accrual: TBD

CRC: TBD

CAR-T

UCI 25-220 (NEW)
Phase III Randomized Study of Consolidation with AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

CRC: Cristian Franco

UCI 25-221 (NEW)
Phase III Study to Evaluate Consolidation Treatment with AZD0120 vs ASCT, in Participants with Newly Dx MM who are Transplant Eligible

Accrual: 0/5

CRC: Cristian Franco

Multiple Myeloma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Multiple Myeloma

1 – 3 prior lines

1 to 3 prior lines

UCI 26-07
Phase 3 Randomized Study Comparing JNJ-79635322 vs. Teclistamab in Participants with R/R MM who Have Received 1-3 Prior Lines of Therapy
Accrual: 0/2
CRC: Alice Ting

1 to 3 prior lines

UCI 26-153
Phase III, Multicenter, Randomized, Open Label Study to Evaluate the Safety & Efficacy of Etentamig + Pomalidomide vs SOC in 2L+ RRMM
Accrual: 0/3
CRC: Alice Ting

≥ 2 prior lines

≥ 2 prior lines

UCI 26-52:
Dose Expansion Cohort
A Phase IB, Multi-center, study of talquetamab in combination with iderdomide and Dexamethasone for the treatment of Relapsed or Refractory Multiple Myeloma
Accrual: 0/5
CRC: TBD

Lenalidomide & anti-CD38 mAb exposure

UCI 26-33
Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Accrual: 1/7
CRC: Alice Ting

≥ 3 prior lines

≥ 3 prior lines

UCI 25-116
A Phase I Antitumor Activity of SIM0500, A Humanized GPTC5D-BCMA-CD3 Trispecific Antibody, in Participants with R/R MM
Accrual: 0/3
CRC: Alice Ting

≥ 3 prior lines

UCI 26-52:
Dose Escalation Cohort
A Phase IB, Multi-center, study of talquetamab in combination with iderdomide and Dexamethasone for the treatment of Relapsed or Refractory Multiple Myeloma
Accrual: 0/5
CRC: TBD

Maintenance

≥ 2 prior lines

ALLIANCE-A062102
(Suspended)
Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in R/R MM
Accrual: 0/5

CRC: Cristian Franco

Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

Supportive Care

UCI 24-170
Intravenous Gammagard for Primary Infection Ppx vs Secondary Infection Prophylaxis in Pts With MM Receiving BCMA directed BsAbs
Accrual: 0/10

CRC: Alice Ting

UCI 26-51 (NEW)
A Phase 3, Prospective, single-arm study to investigate the efficacy, safety and pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic
Accrual: TBD
CRC: TBD

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Stage I or II

COG-AHOD2131
Standard Therapy with Immuno-oncology Therapy for Newly Diagnosed Stage I and II Classical Hodgkin Lymphoma

Accrual: 2/5

CRC: Jeffrey Caluag

Hodgkin's Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

≥ 1 prior line	≥ 2 prior lines	≥ 3 prior lines
	≥ 2 prior lines **UCI 25-21** Pembrolizumab and GVD with ctDNA-guided Consolidation in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma Accrual: 0/5 CRC: TBD	

Diffuse Large B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 23-19
PhIII Odronextamab Comb w/CHOP vs Rituximab Comb w/CHOP

Accrual: 1/5
CRC: Jeffrey Caluag

26-59 (New)
A Phase III study to Evaluate The Efficacy of Surovatamig Combined with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-Chop) in previously untreated Large B-Cell Lymphoma

Accrual: 0/3

CRC: TBD

UCI 24-22
Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-risk Diffuse Large B-cell Lymphoma
Accrual: 0/1

CRC: Jeffrey Caluag

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

CRC: Jeffrey Caluag

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

Tertiary Relapsed/Refractory

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

CRC: Phoebe Lee

2+ Lines

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL
Accrual: 10/15

CRC: Phoebe Lee

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

CRC: Jeffrey Caluag

UCI 26-70 (New)
Leflunomide to reprogram the systemic and neuro-immune microenvironment during CAR-T cell Therapy
Accrual: 0/10
CRC: TBD

UCI 26-64 (New)
A randomized study Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

CRC: TBD

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Low Grade

SWOG S2308
Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Accrual: 4/5

CRC: Jeffrey Caluag

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

CRC: Phoebe Lee

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

TF FL or FL Grade 3B

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL
Accrual: 10/15

CRC: Phoebe Lee

UCI 25-70
Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/7

CRC: Phoebe Lee

On-label & Nonconforming

UCI 25-63
EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

CRC: Pheobe Lee

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

3rd+ Line

UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

Mantle Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

S2506 (NEW)

MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination with Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Participants with Relapsed/Refractory Marginal Zone Lymphoma

Accrual: 0/3

CRC: TBD

Marginal Zone Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 1/6

CRC: Phoebe Lee

26-64 (NEW)
A randomized study of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

CRC: TBD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

UCI 23-114
Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 10/15

CRC: Phoebe Lee

3rd line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

ETCTN-10717
Phase Ib/II Trial of Pidnarulex in MYC Aberrant Lymphoma

Accrual: 0/2

CRC: Jeffrey Caluag

UCI 26-142 (NEW)
A Study to Evaluate the Safety and Efficacy of BGB-16673 in Combination with Sonrotoclax (BGB-11417) Compared to Investigator's Choice in Patients with R/R Waldenström Macroglobulinemia

Accrual: TBD

CRC: TBD

Cutaneous T-Cell Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 21-99
ONO-4685 given as monotherapy (SUSPENDED)

Accrual: 5/10

CRC: Jeffrey Caluag

UCI 25-74 (Reopened)
A Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 6/8

CRC: Jeffrey Caluag

1st Line+

UCI 25-142
Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

CRC: TBD

Newly Diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Peripheral T-Cell Lymphoma

Treatment-Naive

UCI 22-18
Investigation of MRD in patients with treatment-naive systemic T cell lymphoma tx w/ a brentuximab-containing regimen

Accrual: 1/6

CRC: TBD

Post-Induction Treatment

ECOG EA4232
Phase III Study to Evaluate ASCT in Patients with PTCL that Achieved a First CR1 Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

CRC: TBD

UCI 25-74 (Reopened)
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 5/8

CRC: Jeffrey Caluag

2nd Line +

UCI 24-174
ITK Inhibitor Soquelitinib vs. MD Choice SOC Tx in Participants w/ R/R PTCL NOS, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 1/5

CRC: Jeffrey Caluag

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Peripheral T-Cell Lymphoma

	R/R		
	1st Line +	2nd Line +	3rd Line +

UCI 24-174
ITK Inhibitor Soquelitinib vs. MD Choice SOC Tx in Participants w/ R/R PTCL NOS, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 1/5

CRC: Jeffrey Caluag

UCI 21-99
ONO-4685 given as monotherapy (SUSPENDED)

Accrual: 5/10

CRC: Jeffrey Caluag

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

	R/R		
	1st Line +	2nd Line +	3rd Line +

UCI 25-74
Phase I/II Study to Evaluate the Safety & Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 5/8

CRC: Jeffrey Caluag

UCI 25-142
Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

CRC: TBD

Cytotoxic Lymphomas

CAR-T Products

Open to Accrual | Low Accruing | Pending Activation/Suspended

NHL

Autologous

UCI 23-114
Safety & Efficacy of LYL314, a CD19/20 Bispecific CAR-T for R/R B-Cell NHL

Accrual: 10/15

CRC: Phoebe Lee

UCI 25-70
Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/7

CRC: Phoebe Lee

UCI 25-63
EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

CRC: Phoebe Lee

Allogeneic

26-64 (NEW)
A randomized study of Cemacabtagene Ansegedleucel in Participants with MRD After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

CRC: Phoebe Lee

CAR-T Products

Open to Accrual | Low Accruing | Pending Activation/Suspended

MM & Amyloidosis

Autologous

UCI 24-62
Ph III GPRC5D-directed CAR T Cell Therapy in Pts w/ R/R &Lenalidomide-exposed MM (QUINTESSENTIAL-2)

Accrual: 4/5

CRC: Cristian Franco

UCI 26-116 (NEW)
Phase 3 Randomized Study to evaluate the efficacy & safety of NXC-201 compared with CyBorD in Newly Dx Systemic AL Amyloidosis [NEXICART-3]
Accrual: 0/3
CRC: Cristian Franco

UCI 25-220 (NEW)
AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5
CRC: Cristian Franco

UCI 25-221 (NEW)
AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are ASCT Eligible

Accrual: TBA

CRC: Cristian Franco

Allogeneic

Supportive / Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

NHL

Interventional

UCI 23-193
CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy

Accrual: 1/5

CRC: Cristian F. (MM), Phoebe Lee (NHL)

UCI 26-70 (New)
Leflunomide to reprogram the systemic and neuro-immune microenvironment during CAR-T cell Therapy

Accrual: 0/10

CRC: TBD

S2114
Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 1/6

CRC: Phoebe Lee

Observational

UCI 21-184
An Observational Long-term Follow-up Study of Patients who Received Prior Caribou Cell Therapy

Accrual: 7/7

CRC: Heather Franson

Supportive / Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

MM & Amyloidosis

Interventional

Alliance-A062102
(Suspended)
Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

CRC: Cristian F.

Observational

Supportive / Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

HSCT

Interventional

UCI 21-90
Risk-ADAPTed conditioning regimen for AHSCT

Accrual: 38/48

CRC: Mario Diaz

UCI 22-188
Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHSCT

Accrual: 26/50

CRC: Mario Diaz

UCI 24-131 (Suspended)
Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

CRC: Phoebe Lee / Cristian Franco

UCI 25-195
Clinical utility Karius testing for diagnosis & management of suspected infections in adult immunocompromised patients

Accrual: 0/10

CRC: TBD

Observational

UCI 24-110
HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical HSCT

Accrual: 3/7

CRC: Mario Diaz

UCI 26-86
Prospective observational cohort study in US transplant centers

Accrual: 0/30

CRC: Mario Diaz

Other

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 22-194
A Retrospective analysis of L-carnitine for Treatment and/or Prevention of L-Asparaginase Hepatotoxicity during Induction or Salvage Chemotherapy for Hematologic Malignancies
Accrual: TBD

UCI 24-05
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical
Trial Accrual: 32/59

UCI 25-198 (NEW)
A multicenter protocol for haploidentical stem cell transplantation: Optimization of transplant outcomes in a collaborative consortium
Accrual: TBD
CRC: TBD

UCI 26-51 (NEW)
A Phase 3 Single-arm study to investigate IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic Malignancies Treated with B-cell Depleting Therapies
Accrual: TBD
CRC: TBD

UCI 14-89
Hematologic Malignancies Biorepository for human research
Accrual: 325/500

UCI 25-48
RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
Trial Accrual: 12/20

UCI 25-205 (NEW)
Long-term follow-up of ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL
Accrual: 0/6

CRC: TBD

UCI 26-101 (NEW)
ASC4REAL-2: A real-world CM) patient disease registry to describe patient experience and clinical outcomes among patients with CML receiving approved first- or second-line tyrosine kinase inhibitor (TKI) therapy

Accrual: 0/11